SEC Comment Letter 0000000000-25-002308 to Nurix Therapeutics, Inc. (NRIX)
Nurix Therapeutics, Inc.
Date: Feb. 28, 2025 · CIK: 0001549595 · Accession: 0000000000-25-002308
AI Filing Summary & Sentiment
File numbers found in text: 001-39398
Letter
February 28, 2025 Hans van Houte Chief Financial Officer Nurix Therapeutics, Inc. 1700 Owens Street, Suite 205 San Francisco, CA 94158 Re:Nurix Therapeutics, Inc. Form 10-K for Fiscal Year Ended November 30, 2024 File No. 001-39398 Dear Hans van Houte: We have limited our review of your filing to the financial statements and related disclosures and have the following comment. Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe a comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this letter, we may have additional comments. Form 10-K for Fiscal Year Ended November 30, 2024 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations Results of Operations Research and Development Expenses , page 121 1.You disclose on page 117 that you track external research and development costs for each of your drug candidates. Please provide revised disclosure to be included in future filings that breaks out your research and development costs for each of your drug candidates.
In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
February 28, 2025 Page 2 Please contact Eric Atallah at 202-551-3663 or Kevin Kuhar at 202-551-3662 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
February 28, 2025
Hans van Houte
Chief Financial Officer
Nurix Therapeutics, Inc.
1700 Owens Street, Suite 205
San Francisco, CA 94158
Re:Nurix Therapeutics, Inc.
Form 10-K for Fiscal Year Ended November 30, 2024
File No. 001-39398
Dear Hans van Houte:
We have limited our review of your filing to the financial statements and related
disclosures and have the following comment.
Please respond to this letter within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe a
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this letter, we may have additional comments.
Form 10-K for Fiscal Year Ended November 30, 2024
Item 7. Management's Discussion and Analysis of Financial Condition and Results of
Operations
Results of Operations
Research and Development Expenses , page 121
1.You disclose on page 117 that you track external research and development costs for
each of your drug candidates. Please provide revised disclosure to be included in
future filings that breaks out your research and development costs for each of your
drug candidates.
In closing, we remind you that the company and its management are responsible for
the accuracy and adequacy of their disclosures, notwithstanding any review, comments,
action or absence of action by the staff.
February 28, 2025
Page 2
Please contact Eric Atallah at 202-551-3663 or Kevin Kuhar at 202-551-3662 with
any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences